Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 2 天前评分90
正文 · 原文
#ESMO26 💊 RAMIRIS | Phase II/III
👥 317 taxane-pretreated GEA
🔀 FOLFIRI+Ram vs Pac+Ram
❌ Co-primary endpoints not met
⏳ OS: 8.7 vs 7.5 mo (HR 0.95)
🎯 ORR: 25.3% vs 22.6%
✅ PFS: 5.5 vs 3.7 mo (HR 0.70; p=.003)
⚠️ G≥3 AEs: 70% vs 68%
💡 PFS benefit without OS improvement
@OncoAlert
816 浏览 · 12 赞 · 12 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com